Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics
Status:
Recruiting
Trial end date:
2022-02-09
Target enrollment:
Participant gender:
Summary
This is a first time in human (FTIH) study designed to evaluate the safety, tolerability and
pharmacokinetic (PK) profile of single and repeat doses of GSK3923868 inhalation powder in
both healthy participants and asthmatics. This is a 3-part, randomized, double blind, placebo
controlled study of GSK3923868, administered as an inhalation powder blend (GSK3923868
capsules for inhalation) via Mono-dose inhaler in healthy participants (Parts A and B) and in
participants with asthma (Part C). The duration of study participation for each part A, B and
C will be 11, 9 and 8 weeks, respectively.